- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Model N Announces Deal Management for Life Sciences
New solution addresses pricing pressures and streamlines order-to-cash process.
Model N has launched a new Deal Management solution, which connects field sales professionals with operations teams to support the execution and management of the order-to-cash process.
The software-as-a-service solution (SaaS) helps life sciences companies “more efficiently execute contracts by delivering real-time visibility into tiered pricing and rebate data, while providing actionable sales analytics directly to field sales teams,” states the company.
Among the reported benefits for life sciences manufacturers, Deal Management
- improves topline revenue by accessing intelligence previously not accessible to field sales teams
- enhances customer relationships by proactively communicating rebate, tiered pricing and capital equipment status, providing an opportunity to course-correct
- maximizes the Salesforce investment by driving the sales team to Salesforce to access intelligence and manage deals, and
- increases efficiency with field sales and commercial operations teams, decreasing the time to execute and creating more time for value-added tasks.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
